Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 7/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 4/20 | 0.38 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.37 |
| ▸ | CHRNG | P07510 | 1/20 | 0.37 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | CHRND | Q07001 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31160051 | 0.78 | CYP11B2 (0.45) | CYP11B2CYP11B1CYP19A1CYP17A1HRH1 | |
| SCHEMBL28458968 | 0.78 | CYP11B2 (0.45) | CYP11B2CYP11B1CYP19A1CYP17A1HRH1 | |
| SCHEMBL10501106 | 0.78 | CYP11B2 (0.39) | CYP11B2CYP11B1CYP19A1CYP17A1HRH1 | |
| SCHEMBL28340655 | 0.77 | CYP11B1 (0.31) | CYP11B2CYP11B1CYP19A1CYP17A1HRH1 | |
| SCHEMBL10502050 | 0.76 | CYP11B2 (0.38) | CYP11B2CYP11B1CYP19A1CYP17A1HRH1 | |
| SCHEMBL10501604 | 0.75 | CYP11B2 (0.39) | CYP11B2CYP11B1CYP19A1CYP17A1HRH1 | |
| SCHEMBL123160 | 0.75 | GRIA4 (0.35) | KCNH2ELANE | |
| SCHEMBL29857097 | 0.74 | DPP4 (0.41) | CYP11B2CYP11B1CYP19A1CYP17A1HRH1 | |
| SCHEMBL2325813 | 0.74 | CYP11B2 (0.45) | CYP11B2CYP11B1CYP19A1CYP17A1HRH1 | |
| SCHEMBL10503100 | 0.74 | CYP11B2 (0.37) | CYP11B2CYP11B1CYP19A1CYP17A1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359362-B2 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-9359362-B2 | Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-06-07 | — | — | US | disclosed |
| US-9174997-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9174997-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-9174997-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| US-20150045344-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | PH PHARMA CO., LTD. (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20150045344-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | PH PHARMA CO., LTD. (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20150045344-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | PH PHARMA CO., LTD. (KR) | 2015-02-12 | — | — | US | disclosed |
| US-8889700-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-8889700-B2 | 4-(4-cyano-2-thioaryl)dihydropyrimidinones and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| EP-2234985-B1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2012-03-07 | — | — | EP | disclosed |
| EP-2234985-B1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | Bayer Pharma AG (DE) | 2012-03-07 | — | — | EP | disclosed |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-02-10 | — | — | US | disclosed |
| EP-2234985-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009080199-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009080199-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045344-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND USE THEREOF | TNNI3, TNNT2, PC | CYP11B2 4/4885CYP11B1 19/4885CYP19A1 3555/4885 |
| US-20120004203-A1 | TRIAZOLO AND TETRAZOLO PYRIMIDINE DERIVATIVES AS HNE INHIBITORS FOR TREATING COPD | KEAP1, NOX4, NOX5 | CYP11B2 242/4885CYP11B1 347/4885CYP19A1 4453/4885 |
| US-20110034433-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES AND THEIR USE | TNNI3, TNNT2, PC | CYP11B2 8/4885CYP11B1 18/4885CYP19A1 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.